Nanyang New Development Limited Overview
Nanyang New Development Limited is a micro-cap specialty chemicals company listed on SGX Catalist. It was formerly Matex International, a dyestuff maker founded in 1989 and once one of Singapore's fastest-growing China-exposed industrial companies. Its core activity is still the formulation, sourcing and sale of textile dyestuffs and auxiliaries, led by the Megafix® reactive dye range. It also offers colour-measurement systems and some legacy distribution of third-party equipment. After it sold its Taixing manufacturing subsidiaries in 2022, the group became asset-light, with revenue of only S$5.9m in FY2025, about 73% of it from the PRC. A 2025 contest for control ended the founder's 36-year leadership and was followed by a trading suspension, a rebrand and a new PRC-oriented management team. The company now operates as a turnaround and "shell-plus" vehicle. It retains a small dye business, has net cash funded by a placement and convertible notes, and has a mandate to diversify into commodities trading and other new ventures. That diversification has not yet produced material revenue.
Company's own description (FY2025 Annual Report and results filings)
In its FY2025 Annual Report the company describes itself as an established manufacturer, supplier and marketer of quality dyestuffs and specialty chemicals, and of colour-measurement and computer-aided systems. It names its customer industries as textiles, paper, leather, detergents and polymers. It states a vision of becoming an integrated provider of "clean colour science technologies", with Singapore as a centre of excellence. It cites the Megafix® reactive dye series as its flagship. The condensed financial statements give the Company's principal activity as the formulation, manufacturing and sale of specialty chemicals, focused on dyestuff and auxiliaries for the textile industry (FY2025 results, 1 Mar 2026, Note 1). The group reports only geographical segments. Its stated reason is that business-segment reporting is not meaningful because revenue comes mainly from dyestuffs and auxiliaries (FY2025 results, Note 4).
Independent characterisation
The marketing language overstates the scale of the business today. The group is now a small, mostly trading-and-formulation dyestuff business with three features:
No owned dye synthesis capacity in China: since the 2022 sale of Matex Chemicals (Taixing) Co., Ltd (MCT) and Amly Chemicals Co., Ltd (ACL). PPE was only S$0.33m at 31 Dec 2025, after S$0.65m of impairments.
Small, shrinking revenue: Revenue fell from about S$20.9m in FY2021 (derived) to S$5.9m in FY2025, then rebounded to S$4.3m in 1H2026 on aggressive PRC pricing.
A heavy corporate cost base: relative to revenue. G&A was S$6.3m in FY2025, which is 108% of revenue. The FY2025 figure was inflated by S$0.876m of cessation payments and S$0.745m of legal and professional fees.
The 1H2026 results also suggest the PRC business has moved between legal entities. The 60%-owned Shanghai Matex Chemicals Co., Ltd (SMC) recorded only S$0.06m of revenue in 1H2026, against S$1.29m in 1H2025. Over the same period group PRC revenue rose to S$3.77m. Analyst inference: PRC sales now appear to run through wholly owned entities, most likely Matex Chemicals Technologies (Shanghai) and/or Shanghai JingCaiYuan. SMC is left as a loss-making shell with net liabilities of S$5.31m.
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue type | 100% sale of goods recognised at a point in time | FY2025 results Note 4(a) |
| Product vs service mix | About 100% products. Technical service is bundled; no separate service, subscription or licensing revenue is disclosed. | FY2025 results |
| Value-chain position | Mid-stream formulator and marketer. Buys dye intermediates and toll/third-party product ("low-cost sourcing") and sells to textile dye houses and mills. | Placement use-of-proceeds categories ("Low Cost Sourcing"); 2022 sale of manufacturing plants |
| Customer types | Textile dyeing and finishing mills, garment and home-furnishing fabric processors, smaller exposure to paper, leather, detergent and polymer users | FY2025 AR corporate profile |
| End-markets | Apparel and home textiles, mainly PRC; Singapore/Malaysia regional distribution; Indonesia targeted via the Johor relocation | 1H2026 commentary; Ipoh disposal announcement |
| New business mandates | Commodities trading (approved at EGM 13 Jan 2026); membrane materials (Shanghai JingCaiYuan, incorporated 16 Dec 2025); a gold bullion and jewellery venture (Gold Bar Pte Ltd, signed 6 Feb 2026, terminated 1 Apr 2026) | FY2025 results Note 16; EGM minutes |
Strategy
Stated strategy themes (FY2025 AR shareholder message, 1H2026 commentary, AGM minutes 30 Apr 2026)
-
Stabilise the core. Cost discipline, more selective customer and product focus, and tighter credit and inventory control.
-
Clean up the balance sheet. Impairments, rationalising non-core activities and stronger internal controls.
-
Reposition beyond the legacy core. Pursue value-accretive new ventures or acquisitions with "strict focus" on capital efficiency.
-
Expand overseas through partners. Distribution partnerships in Indonesia, Pakistan, Bangladesh and Sri Lanka.
-
Innovate in products. R&D in differentiated dyes, integrated reactive, disperse and auxiliary portfolios, and digital textile printing inks. AGM discussion also mentioned products aimed at younger consumers.
-
Restore trading. The Board told the 2026 AGM it believes SGX-ST requirements have been met and that it is awaiting guidance.
Initiatives in the last 24 months
| Initiative | Date | Status | Quantification | Source |
|---|---|---|---|---|
| Strategic placement to Nanyang Commercial | Nov 2024–Jan 2025 | Completed | S$4.158m gross; net S$3.941m allocated 30% market expansion, 20% low-cost sourcing, 30% new business, 20% working capital | Circular, 23 Dec 2024; 1H2026 |
| Matex YG (Shanghai) associate | Jan 2024 | Operating, loss-making | 25% of RMB12m registered capital; 60% of capital to be paid by 31 Dec 2028; FY2025 revenue S$4k, loss S$367k | Note 11 |
| Diversification into commodities trading | Approved 13 Jan 2026 | Mandate only; one-off chromite ore back-to-back trade in FY2025 | No segment revenue yet | EGM minutes; FY2025 results |
| Shanghai JingCaiYuan (membrane materials) | Incorporated 16 Dec 2025 | Start-up | — | Note 10 |
| Gold Bar Pte. Ltd. (bullion brokering and jewellery retail) | Signed 6 Feb 2026 | Terminated 1–2 Apr 2026; disagreement over GBPL's proposed change of business direction | Intended 55% stake (110,000 shares); about S$1m investment | SGX filings; The Edge |
| Convertible notes | 23 Jan 2026 | Funded 9 Mar 2026 | S$4.158m; 50% working capital, 50% new business | FY2025 AR; 1H2026 |
| Sales force restructuring | 2025–2026 | Ongoing | Headcount 65 to 60; personnel cost -31% in 1H2026 | 1H2026 |
| Ipoh to Johor relocation | Jun–Sep 2026 | SPA signed | RM1.9m disposal proceeds | SGX filings |
| New Singapore laboratory | 2,026 | In progress | Equipment prepayments (1H2026 prepayments S$0.178m) | 1H2026 |
| Sustainability targets | FY2025 SR | Set | Short/medium/long-term intensity targets (see Section 20) | FY2025 SR |
Medium-term targets and guidance
No financial guidance or medium-term revenue or margin targets have been issued. The 1H2026 announcement states that no forecast or prospect statement had been disclosed.
Products & Services
Segment attribution is the analyst's, because the company reports no product segments. Pricing is not publicly disclosed for any product.
Certifications and credentials. 99 products certified to ZDHC Level 3 (MRSL). Collaboration with bluesign®, ETAD and Cradle to Cradle bodies. ISO 9001 and ISO 14001 systems. OH&S procedures aligned to OHSAS 18001. Holder of the LowCarbonSG logo (FY2025 Sustainability Report).
Product Portfolio
| Product / brand | Category | Description and capabilities | Target customer | Launch / latest year | Source |
|---|---|---|---|---|---|
Megafix® reactive dye series | Dyestuffs (cellulosic) | Flagship reactive dyes for cotton and cellulosics; the company presents it as evidence of its in-house innovation | Cotton knit and woven dyehouses | Long-standing; year not publicly disclosed | FY2025 AR |
Megafix® RE | Low-temperature reactive dyeing | Low-temperature exhaust dyeing that cuts energy use | Energy-cost-sensitive mills | — | FY2025 Sustainability Report; stocks.cafe |
Megaperse CF | Disperse dye system | One-bath scouring, bleaching and dyeing; fewer process steps | Polyester/cotton blend processors | — | stocks.cafe profile |
Megaperse SP | High-fastness disperse dyes | High-fastness dyes for polyester/spandex blends | Activewear and stretch-fabric dyers | — | stocks.cafe profile |
Megapro® solutions | Auxiliaries / process chemicals | Efficiency auxiliaries that reduce energy use and replace conventional chemicals | Dyehouses | — | FY2025 Sustainability Report |
Megapro ECO® | Salt-free dyeing auxiliary | Removes the need for salt in cotton reactive dyeing and lowers water and energy cost | Cotton dyers facing effluent limits | — | FY2025 Sustainability Report |
Mebyo® Technology | Bio-based cleaning | Probiotic/prebiotic biodegradable cleaning alternative to conventional products | Institutional and industrial cleaning | — | FY2025 Sustainability Report |
Optical brighteners | Specialty chemicals | Formulated and sold through Unimatex (Malaysia) | Textile, paper and detergent users | — | Note 10 |
Auxiliaries and textile chemicals | Specialty chemicals | Pre-treatment, dyeing and finishing auxiliaries | Mills | — | Corporate profile |
Colour measurement and computer-aided systems | Equipment and systems | Supplied and serviced through MatexMega (65%); historically included distribution of X-Rite spectrophotometers | Mill QC laboratories | — | SGX corporate information; Note 10 |
Specialty process equipment and computerised control systems (third-party) | Distribution | Third-party equipment distribution | Mills | Legacy | SGX corporate information |
Ultra-Fresh antimicrobial products (third-party) | Distribution | Antimicrobial textile finishes | Fabric finishers | Legacy | SGX corporate information |
Garments and textile products trading | Trading | Import/export and wholesale through Dedot Trading (Shanghai) | Trade buyers | — | Note 10 |
Membrane materials | New business | Sale of new membrane materials through Shanghai JingCaiYuan | — | Entity formed Dec 2025 | Note 10 |
Commodities trading | New business (mandate) | Shareholder-approved diversification. FY2025 included a one-off back-to-back chromite ore trade, booked as other income. | — | Mandate Jan 2026 | FY2025 results; EGM minutes |
Digital textile printing inks | Development focus | Management names the shift to digital printing inks as a growth area. No product launch disclosed. | Digital printers | Planned | 1H2026 commentary |
“—” = not publicly disclosed.
Financial Narrative
Income statement
The FY2022 EPS of 2.33 cents is the fully diluted figure reported by The Edge. FY2022 other income of about S$12.5m was mainly gains on disposal of MCT and ACL (The Edge's article prints "US$12.5 million", which appears to be a typo for S$). FY2021–FY2022 "net income" is the "earnings" figure The Edge reported; whether it is attributable or total is not specified.
Margins and growth
Revenue CAGR. FY2021–FY2025: about -27.2% a year (using derived FY2021). FY2023–FY2025 (post-disposal basis): -10.7% a year.
Commentary: revenue. There are two distinct phases. FY2021–FY2023 is structural shrinkage, driven by the 2022 sale of the Taixing plants (MCT and ACL), COVID-era weakness in PRC textiles and Sri Lanka's 2022 crisis. FY2023–FY2025 is cyclical and competitive erosion. Management attributes the FY2025 decline of 16.3% to weak global consumption, US/EU slowdown, low-cost import competition and overcapacity (FY2025 results, para 8).
Commentary: gross margin. Gross margin peaked at about 21–22% in FY2023–FY2024, when the asset-light sourcing model worked. It compressed to 14.8% in FY2025, and to 9.3% in 2H2025, because of price competition and S$0.313m of inventory write-downs at the China subsidiary. In 1H2026 it recovered to 17.6%, but management says this came from deliberate price cuts to regain share. That points to volume-led rather than margin-led recovery.
Commentary: cost base and FY2025 losses. G&A rose 56% to S$6.34m in FY2025. The FY2025 loss before tax of S$7.74m includes these non-recurring items:
Even after adding back about S$3.9m, the underlying loss is about S$3.8m. That is consistent with FY2023 and FY2024 and shows a structural loss of roughly S$3.3–4.0m a year before the 2026 restructuring.
Balance sheet
FY2021–FY2022 total assets, liabilities, equity and cash are from TipRanks (secondary).
Commentary. Equity attributable to owners fell by more than half in two years, from S$12.7m (FY2023) to S$6.1m (FY2025), despite the S$4.158m placement in January 2025. Losses have absorbed more than the new capital. The cash balance is the group's main asset, at about 71% of total assets in FY2025. Non-controlling interests have been increasingly negative because 60%-owned SMC has net liabilities of S$5.09m. Some intra-group liabilities sit in SMC (SMC current liabilities S$6.86m against current assets S$1.76m), which creates possible ring-fencing questions for PRC creditors.
Interim position, 30 June 2026 (1H2026 results, 11 Aug 2026)
Commentary. Revenue rose 70% in 1H2026 and the loss nearly halved, helped by personnel costs down to S$0.881m from S$1.282m and FX losses down to S$1k from S$397k. On a TTM basis (FY2025 less 1H2025 plus 1H2026), revenue is about S$7.63m and the net loss about S$6.73m. The cash rise to S$9.45m was funded by debt (convertible notes), not by operations. On an adjusted basis, net cash after the notes and loans is about S$3.8m.
Cash flow
FY2021–FY2023 capex is derived as OCF minus FCF from TipRanks. FY2024 investing outflows included S$1.3m for an "other long-term investment" (unquoted equity, later written down to nil through OCI), S$0.225m for the associate and a S$1.138m refund to a former subsidiary.
Commentary. Operating cash burn has accelerated: -S$0.46m (FY2023), -S$2.40m (FY2024), -S$5.19m (FY2025), then -S$2.47m in 1H2026. The S$15.7m of disposal proceeds received in 2022–2023 has been largely consumed by losses, investments and debt repayment. External capital raised since January 2025 totals S$8.3m (placement plus convertible notes). Of the placement, S$2.36m was unutilised at 11 Aug 2026, and none of the S$4.105m net note proceeds had been used.
Key ratios
ROIC and net debt/EBITDA are not meaningful: invested capital is negative because of net cash, and EBITDA is negative. Ratios are analyst calculations from filed figures.
Inflections. (1) The 2022 disposals turned the group into a cash-rich, asset-light vehicle. (2) The 2025 control contest added at least S$1.6m of one-off costs. (3) 1H2026 shows the first sign of operating stabilisation (revenue up, G&A down 35%), but gross margin is being sacrificed and the convertible notes add interest cost (finance expenses of S$0.112m in 1H2026, against S$0.027m in 1H2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Principal activity | Country | Group interest (%) |
|---|---|---|---|
Nanyang New Development Limited | Holding; dyestuff formulation and sale | Singapore | Parent |
Matex Holdings Pte Ltd | General wholesale trading and dyestuffs manufacturing | Singapore | 100 |
Shanghai Matex Chemicals Co., Ltd (SMC) | Sale of dyestuffs | PRC | 60 |
Unimatex Sdn Bhd (USB) | Formulation, manufacture and sale of dyestuffs, auxiliaries and optical brighteners | Malaysia | 100 |
Matex Chemicals Technologies (Shanghai) Co., Ltd (MTL) | General wholesale trading | PRC | 100 |
Dedot Trading (Shanghai) Co., Ltd | Import/export and wholesale of garments, textiles and chemicals | PRC | 100 (via MHPL) |
MatexMega Pte. Ltd. | Manufacture and repair of measuring devices and process-control equipment | Singapore | 65 (via MHPL) |
Matex Holdings (HK) Limited | General wholesale trade | Hong Kong | 100 (via MHPL) |
Shanghai JingCaiYuan New Materials Co., Ltd (incorporated 16 Dec 2025) | Sale of new membrane materials; technology and agency import/export | PRC | 100 (via MTL) |
Matex YG (Shanghai) Material Tech Ltd (associate) | Materials technology | PRC | 25 (via MTL) |
Revenue by Segment
| Segment metric (SGD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC external revenue (SGD Mn) | — | 4.785 | 4.304 |
Other Asia Pacific external revenue (SGD Mn) | — | 2.217 | 1.555 |
PRC inter-segment revenue (SGD Mn) | — | 3.068 | 2.078 |
PRC segment result (SGD Mn) | — | -1.278 | -3.087 |
Other Asia Pacific segment result (SGD Mn) | — | -2.239 | -8.840 |
Eliminations, segment result (SGD Mn) | — | 0.007 | 4.168 |
Group revenue (SGD Mn) | 7.354 | 7.002 | 5.859 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment ratios
| Segment ratios | FY2024 | FY2025 |
|---|---|---|
PRC share of group revenue (%) | 68.3 | 73.5 |
Other Asia Pacific share of group revenue (%) | 31.7 | 26.5 |
PRC external revenue growth YoY (%) | — | -10.1 |
Other Asia Pacific external revenue growth YoY (%) | — | -29.9 |
PRC segment margin (result / external revenue, %) | -26.7 | -71.7 |
Revenue by Segment (1H2025–1H2026)
| Segment metric (SGD Mn) | 1H2025 | 1H2026 |
|---|---|---|
PRC external revenue (SGD Mn) | 1.848 | 4.085 |
Other Asia Pacific external revenue (SGD Mn) | 0.934 | 0.518 |
Eliminations (SGD Mn) | -0.267 | -0.319 |
PRC segment result (SGD Mn) | -0.573 | -0.325 |
Other Asia Pacific segment result (SGD Mn) | -1.735 | -0.874 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (SGD Mn) | 20.9 | 14.6 | 7.354 | 7.002 | 5.859 |
Gross profit (SGD Mn) | 2.63 | 2.5 | 1.608 | 1.465 | 0.865 |
Other income (SGD Mn) | 0.334 | 12.5 | 0.048 | 0.191 | 0.332 |
Operating income, EBIT excl. associate and net finance (SGD Mn) | — | — | — | -3.450 | -7.668 |
EBITDA, EBIT + D&A (SGD Mn) | — | — | — | -2.775 | -7.444 |
Pre-tax income (SGD Mn) | — | — | -4.025 | -3.276 | -7.741 |
Net income, total (SGD Mn) | -4.9 | 7.3 | -4.041 | -3.289 | -7.746 |
Net income attributable to owners (SGD Mn) | — | — | -3.310 | -2.654 | -6.771 |
EPS basic (SGD cents) | — | 2.33 | -0.98 | -0.73 | -1.34 |
EPS diluted (SGD cents) | — | 2.33 | -0.98 | -0.73 | -1.34 |
Dividends per share (SGD cents) | — | — | — | 0 | 0 |
Weighted avg shares (M) | — | — | 337.3 | 361.7 | 503.9 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 12.6 | 17.2 | 21.9 | 20.9 | 14.8 |
Operating (EBIT) margin (%) | — | — | — | -49.3 | -130.9 |
EBITDA margin (%) | — | — | — | -39.6 | -127.1 |
Net margin, total (%) | -23.4 | 50.0 | -54.9 | -47.0 | -132.2 |
Revenue growth YoY (%) | — | -30.3 | -49.6 | -4.8 | -16.3 |
FY2025 non-recurring / non-cash item
| FY2025 non-recurring / non-cash item | SGD Mn |
|---|---|
Cessation payments (Dr Tan Pang Kee, Mr Tan Guan Liang, Ms Lok Fong Meng) | 0.876 |
Legal and professional fees (settlement and corporate exercises) | 0.745 |
Impairment of financial assets (incl. S$0.95m irrecoverable bills/other receivable) | 1.061 |
Impairment of non-financial assets (PPE) | 0.651 |
Inventory write-down | 0.313 |
FX loss (MYR Bn weakness) | 0.256 |
Total identified | 3.902 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (SGD Mn) | 30.22 | 24.25 | 21.398 | 15.244 | 11.848 |
Cash and equivalents incl. fixed deposits (SGD Mn) | 6.46 | 11.92 | 16.37 | 8.856 | 8.355 |
Total liabilities (SGD Mn) | 23.14 | 9.15 | 9.152 | 7.285 | 7.815 |
Total equity (SGD Mn) | 7.08 | 15.10 | 12.246 | 7.959 | 4.033 |
Equity attributable to owners (SGD Mn) | — | — | 12.701 | 9.049 | 6.053 |
Non-controlling interests (SGD Mn) | — | — | -0.455 | -1.090 | -2.020 |
Short-term debt: term loans + current leases (SGD Mn) | — | — | — | 1.265 | 1.847 |
Long-term debt: non-current leases (SGD Mn) | — | — | — | 0.226 | 0.022 |
Total debt (SGD Mn) | — | — | — | 1.491 | 1.869 |
Net debt, negative = net cash (SGD Mn) | — | — | — | -7.365 | -6.486 |
Goodwill and intangibles (SGD Mn) | — | — | — | 0 | 0.008 |
Working capital (SGD Mn) | — | — | 11.090 | 6.174 | 3.714 |
NAV per share (SGD cents) | — | — | 3.51 | 2.50 | 1.17 |
Cash Flow and Margin Analysis (%)
| Metric | 1H2025 | 1H2026 |
|---|---|---|
Revenue (SGD Mn) | 2.515 | 4.284 |
Gross profit (SGD Mn) | 0.555 | 0.755 |
Gross margin (%) | 22.1 | 17.6 |
G&A expenses (SGD Mn) | 2.482 | 1.622 |
Loss before tax (SGD Mn) | -2.313 | -1.311 |
Net loss, total (SGD Mn) | -2.318 | -1.306 |
Net loss attributable (SGD Mn) | -2.085 | -1.292 |
EPS basic (SGD cents) | -0.49 | -0.25 |
Operating cash flow (SGD Mn) | -3.455 | -2.472 |
Cash at period end (SGD Mn) | 10.050 | 9.447 |
Balance Sheet and Per-Share Data (31-Dec-2025–30-Jun-2026)
| Balance sheet item (SGD Mn) | 31-Dec-2025 | 30-Jun-2026 |
|---|---|---|
Cash (SGD Mn) | 8.355 | 9.447 |
Term loans (SGD Mn) | 1.832 | 1.230 |
Convertible notes (SGD Mn) | 0 | 4.158 |
Lease liabilities (SGD Mn) | 0.037 | 0.293 |
Total equity (SGD Mn) | 4.033 | 2.742 |
Equity attributable (SGD Mn) | 6.053 | 4.853 |
NAV per share (SGD cents) | 1.17 | 0.94 |
Working capital (SGD Mn) | 3.714 | 6.428 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (SGD Mn) | 0.238 | -1.17 | -0.456 | -2.403 | -5.194 |
Capex: PPE purchases (SGD Mn) | 0.273 | 0.08 | 0.298 | 0.566 | 0.085 |
Free cash flow (SGD Mn) | -0.035 | -1.25 | -0.754 | -2.969 | -5.279 |
Investing cash flow (SGD Mn) | -0.267 | 11.77 | 3.82 | -3.224 | 0.171 |
Financing cash flow (SGD Mn) | 1.91 | -4.82 | 1.12 | -1.876 | 4.719 |
Equity issued (SGD Mn) | — | — | — | 0 | 4.158 |
Dividends paid (SGD Mn) | — | — | — | 0 | 0 |
Share buybacks (SGD Mn) | — | — | — | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE, attributable loss / ending attributable equity (%) | -26.1 | -29.3 | -111.9 |
ROA, total loss / ending total assets (%) | -18.9 | -21.6 | -65.4 |
Current ratio (x) | 2.29 | 1.89 | 1.48 |
Debt / equity (x) | — | 0.19 | 0.46 |
Interest coverage, EBIT / interest expense (x) | — | -67.6 | -108.0 |
Asset turnover, revenue / average assets (x) | 0.32 | 0.38 | 0.43 |
Days sales outstanding, trade + notes (days) | — | 95 | 67 |
Days inventory outstanding (days) | — | 102 | 86 |
Days payables outstanding (days) | — | 84 | 73 |
Cash conversion cycle (days) | — | 113 | 80 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC revenue (SGD Mn) | — | 4.785 | 4.304 |
Singapore revenue (SGD Mn) | — | 1.560 | 1.044 |
Malaysia revenue (SGD Mn) | — | 0.657 | 0.511 |
Total revenue (SGD Mn) | 7.354 | 7.002 | 5.859 |
Growth and mix (%)
| Growth and mix (%) | FY2024 | FY2025 |
|---|---|---|
PRC growth YoY (%) | — | -10.1 |
Singapore growth YoY (%) | — | -33.1 |
Malaysia growth YoY (%) | — | -22.2 |
PRC share (%) | 68.3 | 73.5 |
Singapore share (%) | 22.3 | 17.8 |
Malaysia share (%) | 9.4 | 8.7 |
Revenue by Region (1H2025–1H2026)
| Region | 1H2025 | 1H2026 |
|---|---|---|
PRC revenue (SGD Mn) | 1.581 | 3.766 |
Singapore revenue (SGD Mn) | 0.662 | 0.369 |
Malaysia revenue (SGD Mn) | 0.272 | 0.149 |
Share Price & Returns
| Reference point | Date | Price (SGD) | Source |
|---|---|---|---|
Trading level | 4 May 2020 | 0.019 | The Edge Singapore |
Close | 28 Feb 2023 | 0.025 | The Edge Singapore |
VWAP | 30 Oct 2024 | 0.018 | MT Newswires |
Placement price | 24 Jan 2025 | 0.027 | Subscription announcement |
Last traded before suspension | Jul 2025 | 0.022 | The Edge Singapore (Apr 2026) |
Convertible note conversion price | Jan 2026 | 0.0198 | 1H2026 results |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap (SGD Mn) | 11.35 | 515.7m shares × S$0.022 |
P/B (x) | 2.34 | Attributable equity S$4.853m (30 Jun 2026) |
Price / NAV per share (x) | 2.34 | NAV 0.94 cents |
EV (SGD Mn) | 7.58 | Market cap + debt S$5.68m (loans, leases, notes) - cash S$9.45m; excludes negative NCI |
EV / Sales TTM (x) | 0.99 | TTM revenue about S$7.63m |
Capital Markets
| Item | Detail |
|---|---|
Analyst consensus | None; no sell-side coverage identified |
Dividend history and policy | No dividends for FY2024, FY2025 or 1H2026; the Board cites the operational loss position. No formal policy disclosed. |
Buyback authorisation | None disclosed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Capital raised since 2023 | S$1.25m (CSF, 2023); S$4.158m placement (Jan 2025); S$4.158m convertible notes (Mar 2026) |
Capital Instruments
| Instrument | Amount (SGD Mn) | Maturity | Security |
|---|---|---|---|
PRC bank term loan | 1.230 | Within 12 months; rollover at bank's discretion | Corporate guarantee plus directors' joint and several guarantees |
Unsecured convertible notes | 4.158 | Aug 2027 | Unsecured; convertible at S$0.0198 |
Lease liabilities | 0.293 | 2026–2028 | Hire purchase (S$6k) secured on asset |
Analyst Conclusions
Management guidance
There is no quantitative guidance. Management expects a challenging near-term environment. It intends to stabilise the core business, expand overseas through partners, benefit from expected normalisation of PRC dye prices, and pursue value-accretive new ventures (FY2025 AR outlook; 1H2026 para 10).
Consensus
No sell-side consensus exists.
Bull case
-
The turnaround is visible. 1H2026 revenue rose 70% and the loss before tax narrowed 43%. If 2H2026 matches 1H2026, FY2026 revenue would be about S$8.5m and the loss would roughly halve from FY2025.
-
Cash supports the valuation. Cash of S$9.45m is close to the S$11.35m market cap. EV is only about S$7.6m, roughly 1x TTM sales.
-
Resumption is a catalyst. A newly constituted board, a sponsor in place, and statements that SGX requirements have been met could bring an SGX no-objection, with re-rating potential.
Bear case
-
Structural losses. Even excluding about S$3.9m of FY2025 one-offs, the core lost about S$3.8m. The 1H2026 recovery was bought through lower margins, with gross margin down 4.5 percentage points.
-
Dilution and control risk. Conversion at S$0.0198, below the last trade, would issue 210m shares and could hand effective influence to the noteholders.
-
Delisting and liquidity risk. The suspension has passed 14 months. If the notes are not converted, S$4.16m is repayable in Aug 2027, against annual cash burn of S$5m in FY2025.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| SGX RegCo decision on resumption of trading | Unknown | Liquidity, valuation, delisting risk |
| FY2026 results (2H2026 trends) | By end Feb 2027 | Tests whether the turnaround is sustainable |
| Deployment of S$3.2m new-business funds | Rolling | Quality of capital allocation |
| Convertible note conversion decisions | Before Aug 2027 | Dilution and control |
| Completion of Ipoh disposal and Johor relocation | 2H2026 | Cost and logistics |
| Singapore HQ and lab relocation | From Sep 2026 | Operational continuity |
| Shareholding changes (Nanyang Commercial, Khua bloc, noteholders) | Rolling | Control dynamics |
| Statistics of shareholdings / free float in FY2026 AR | Apr 2027 | Catalist free-float compliance |
| Gross margin trajectory in the PRC | 2H2026 | Pricing discipline |
Analyst verdict
Nanyang New Development is best understood as a restructured shell built around a residual dyestuff franchise. It is not an operating specialty-chemicals company in the usual sense. The former Matex International sold its manufacturing heart in 2022 and then lost most of the disposal cash to recurring losses, investments that later had to be written off, and a costly 2025 boardroom battle. That battle ended the founding family's 36-year leadership and led to a suspension that has lasted more than fourteen months. The new board, aligned with Nanyang Commercial and chaired by an experienced independent former SGX regulator, has done the necessary clean-up work. It has impaired doubtful assets, settled with former management, cut personnel costs, secured S$4.16m of note funding and delivered a credible first-half rebound in PRC sales.
The economics remain fragile. FY2025 revenue of S$5.9m cannot support a listed-company cost base. Expensed R&D is effectively nil. The 1H2026 recovery was achieved by sacrificing margin in an overcapacity market where scale producers set prices. The diversification mandate has so far produced one aborted bullion venture and a one-off ore trade. The convertible notes, priced below the last traded share price, put a large share of future value in noteholders' hands and leave open the question of who will control the company.
On the last traded price, the equity is valued at about 2.3x book and about 1x TTM sales, with net cash providing some downside cushion. Investors are mainly buying an option on resumption of trading and a successful pivot, not the earnings of a proven business. We regard the risk/reward as speculative and event-driven. Monitor four things: an SGX no-objection, sustained 2H2026 gross margins above about 18%, disciplined deployment of new-business funds, and transparent disclosure of shareholdings and conversions. Without progress on resumption and recurring profitability by FY2026, delisting and further dilution are realistic outcomes.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed | Background | Education |
|---|---|---|---|---|
Mr James Kho Chung Wah | Non-Executive Chairman and Independent Director; AC Chairman | ID from 15 May 2025; Chairman from 26 Nov 2025 | CEO and co-founder of Willan Capital Pte. Ltd.; senior roles at multinational and investment banks; began career in SGX Issuer Regulation; ID of Rich Capital Holdings and OceanScape International | B.Bus (Hons), NTU; CFA |
Dr Liu Shen | Executive Director and Chief Technical Officer | 17 Oct 2025 | 20+ years in applied and fine chemicals in the PRC: GM Fuzhou Xingchen Pharmaceutical (2021–22); GM Hengshui Quark Biotechnology (2023–24); adviser at Hunan Ruiguan Biotechnology (2024–25); DGM, Hunan Jingfeng Chemical Technology (2025). Executive Manager of Amly Chemicals (2014–21) and General Affairs Manager at SMC (2012–14). Nominated in Nanyang Commercial's July 2025 requisition. | PhD Applied Chemistry, Dalian University of Technology; MSc, Qiqihar University |
Dr Fu ShaoHai | Independent Director; RC Chairman | 5 Feb 2026 | Dean, College of Textile Science & Engineering, Jiangnan University (2017–Nov 2025); now Director of Development Planning at Jiangnan University | PhD Textile Science & Engineering, Jiangnan; MSc and BSc, Qingdao University |
Ms Sim Kai Li | Independent Director | Appointment announced 24 Jul 2026 | — | — |
Executive Leadership Team
| Name | Title | Since | Background |
|---|---|---|---|
Mr Chen HongBo | Chief Executive Officer | — | Independent investor since 2018 in healthcare, gaming/eSports, automotive aftermarket, government data services and community sports; prior senior management roles |
Mr Seow Han Khye | CFO and Joint Company Secretary (co-sec from 5 Feb 2026) | CFO since at least 2023 | Former CFO of Luma Group; FCCA |
Ms Shirley Tan Sey Liy | Joint Company Secretary | Reappointed | FCS, FCG |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
5 Apr 2024 | Dr John Chen Seow Phun retires as Chairman | Long-serving chairman |
1 May 2024 | Mr Chiang Yao Chong appointed ID and AC Chair | Board refresh |
1 Aug 2024 | Mr Wang Daofu re-designated Non-Executive Chairman | Succession |
28 Apr 2025 | Foo Der Rong retires; Chiang Yao Chong not re-elected at AGM | First visible shareholder dissent after Nanyang Commercial's entry |
1/15 May 2025 | Chng Hee Kok and James Kho appointed IDs | Rebuild of independent bench |
7 Jul 2025 | Nanyang Commercial requisitions removal of Dr Tan and Mr Tan; nominates Liu Shen and Kok Jun Yan as EDs | Control contest |
16 Sep 2025 | Dr Tan Pang Kee, Mr Tan Guan Liang and Mr Wang Daofu resign; Tan Chong Huat appointed Chairman; Dr Danny Oh appointed ED | Settlement plus minority-requisitioned EGM |
30 Sep 2025 | Tan Chong Huat re-designated independent | Catalist compliance |
17 Oct 2025 | Dr Liu Shen appointed ED | Nanyang Commercial-aligned management |
By 5 Nov 2025 | Mr Chen Hongbo appointed CEO | New management |
5 Nov 2025 | Tan Chong Huat resigns, citing personal commitments and stabilised operations | Interim chair exits |
26 Nov 2025 | James Kho becomes Chairman | — |
5 Feb 2026 | Dr Fu ShaoHai appointed ID | Textile-science expertise |
30 Apr 2026 | Chng Hee Kok retires | — |
24 Jul 2026 | Ms Sim Kai Li appointed ID | — |
Major Shareholders
| Holder | Shares | Stake (%) | Basis / date | Source |
|---|---|---|---|---|
Nanyang Commercial Management Pte. Ltd. (sole shareholder and director: Mr Wang Weidong) | 154,000,000 | 29.86 | Since 24 Jan 2025 | Requisition notice, 7 Jul 2025 |
Dr Tan Pang Kee (founder) | — | 21.82 in 2020, before dilution | Current holding not publicly verified | The Edge (2020) |
Mr Khua Kian Keong (direct and via CSF Fund I / DBS Nominees) | — | 14.96 in 2020, before dilution | Directed the "New Requisitionists" in Aug–Sep 2025 | The Edge (2020); TipRanks |
CSF Fund I Pte. Ltd. | — | Became substantial shareholder after the 2023 placement | 2023 | Matex announcement, 5 Jun 2023 |
Convertible note holders: Ascentas Capital Management Limited and Li Baohua | 210,000,000 potential | 28.9 of enlarged capital if fully converted | Notes due Aug 2027 | 1H2026 results |
Competitive Landscape
Key Competitors
| # | Competitor | Listing | Segment overlap | Relative scale vs NNDL | Positioning vs NNDL |
|---|---|---|---|---|---|
| 1 | Zhejiang Longsheng Group (owner of DyStar) | SSE: 600352 | Disperse and reactive dyes, auxiliaries | Several orders of magnitude larger | Global leader; integrated intermediates |
| 2 | DyStar | Subsidiary of Longsheng | Reactive/disperse dyes, auxiliaries, colour services | Multinational | Premium brand-compliant supplier |
| 3 | Zhejiang Runtu Co., Ltd | SZSE: 002440 | Disperse and reactive dyes | Several orders of magnitude larger | Low-cost PRC scale producer |
| 4 | Zhejiang Jihua Group | SSE: 603980 | Dyes and intermediates | Much larger | PRC integrated producer |
| 5 | Jiangsu Yabang Dyestuff | SSE: 603188 | Disperse dyes | Much larger | PRC producer |
| 6 | Archroma (incl. ex-Huntsman Textile Effects) | Private (SK Capital) | Dyes, auxiliaries, sustainable solutions | Multinational | Sustainability-led premium |
| 7 | Atul Ltd | NSE: ATUL | Reactive and other dyes | Much larger | Indian integrated chemicals |
| 8 | Kiri Industries | NSE: KIRIINDUS | Reactive dyes, intermediates | Much larger | Indian reactive-dye specialist |
| 9 | Bodal Chemicals | NSE: BODALCHEM | Reactive dyes, intermediates | Much larger | Integrated Indian producer |
| 10 | Everlight Chemical Industrial | TWSE: 1711 | Disperse and reactive dyes | Much larger | Taiwanese specialty dyes |
| 11 | CHT Group | Private (Germany) | Auxiliaries, dyes | Multinational | Auxiliary specialist |
Competitor Detail
| Metric | NNDL FY2025 |
|---|---|
Revenue (SGD Mn) | 5.859 |
Revenue growth (%) | -16.3 |
Gross margin (%) | 14.8 |
Net margin (%) | -132.2 |
R&D / revenue (%) | 0.03 |



